Abstract
The in vitro and in vivo effects of NY-198 against Legionella pneumophila were compared with those of ciprofloxacin. The MIC of NY-198 against 15 standard reference strains of Legionella of various species, between 0.03 and 0.125 micrograms/ml, was the same as that of ciprofloxacin. The peak concentration of NY-198 in the lungs and sera of guinea pigs with experimentally induced Legionella pneumonia was higher than that of ciprofloxacin after oral administration. The overall survival rate was higher in animals treated with NY-198 than in those treated with ciprofloxacin. Thus, NY-198 appears valuable in the treatment of Legionnaires disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brown S., Warnnissorn T., Biddle J., Panikabutra K., Traisupa A. Antimicrobial resistance of Neisseria gonorrhoea in Bangkok: is single-drug treatment passé. Lancet. 1982 Dec 18;2(8312):1366–1368. doi: 10.1016/s0140-6736(82)91271-5. [DOI] [PubMed] [Google Scholar]
- Dournon E., Rajagopalan P., Vilde J. L., Pocidalo J. J. Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. J Antimicrob Chemother. 1986 Apr;17 (Suppl B):41–48. doi: 10.1093/jac/17.suppl_b.41. [DOI] [PubMed] [Google Scholar]
- Edelstein P. H., Calarco K., Yasui V. K. Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs. Am Rev Respir Dis. 1984 Nov;130(5):849–856. doi: 10.1164/arrd.1984.130.5.849. [DOI] [PubMed] [Google Scholar]
- Fitzgeorge R. B., Gibson D. H., Jepras R., Baskerville A. Studies on ciprofloxacin therapy of experimental Legionnaires' disease. J Infect. 1985 May;10(3):194–203. doi: 10.1016/s0163-4453(85)92438-7. [DOI] [PubMed] [Google Scholar]
- Hirose T., Okezaki E., Kato H., Ito Y., Inoue M., Mitsuhashi S. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother. 1987 Jun;31(6):854–859. doi: 10.1128/aac.31.6.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Horwitz M. A., Silverstein S. C. Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes. J Clin Invest. 1980 Sep;66(3):441–450. doi: 10.1172/JCI109874. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ito A., Hirai K., Inoue M., Koga H., Suzue S., Irikura T., Mitsuhashi S. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother. 1980 Feb;17(2):103–108. doi: 10.1128/aac.17.2.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koga H. High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1987 Dec;31(12):1904–1908. doi: 10.1128/aac.31.12.1904. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saito A., Koga H., Shigeno H., Watanabe K., Mori K., Kohno S., Shigeno Y., Suzuyama Y., Yamaguchi K., Hirota M. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J Antimicrob Chemother. 1986 Aug;18(2):251–260. doi: 10.1093/jac/18.2.251. [DOI] [PubMed] [Google Scholar]
- Saito A., Sawatari K., Fukuda Y., Nagasawa M., Koga H., Tomonaga A., Nakazato H., Fujita K., Shigeno Y., Suzuyama Y. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother. 1985 Jul;28(1):15–20. doi: 10.1128/aac.28.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saito A., Shimoda T., Nagasawa M., Tanaka H., Ito N., Shigeno Y., Yamaguchi K., Hirota M., Nakatomi M., Hara K. [The first case of Legionnaires' disease in Japan (author's transl)]. Kansenshogaku Zasshi. 1981 Feb;55(2):124–128. doi: 10.11150/kansenshogakuzasshi1970.55.124. [DOI] [PubMed] [Google Scholar]